Microneedle

Aesthetics Biomedical® Hires Two New Executives to Join the Company's Leadership Team to Fuel Growth Trajectory

Retrieved on: 
Wednesday, July 27, 2022

PHOENIX, July 27, 2022 /PRNewswire-PRWeb/ -- Aesthetics Biomedical® Inc. (ABM), in its ongoing efforts to meet the increasing demand for its revolutionary aesthetic products and distribution growth, is continuing to build its executive team recruiting top industry experts Derek Harmon as Vice President of U.S. Sales and Don Selvey, NMD, MS as Vice President of Regulatory respectively. Mr. Harmon and Dr. Selvey will play pivotal roles in the company's expansion and national distribution of current products including the legacy Vivace® Microneedle RF treatment and device, SoME® PRP Skincare and focus on the new era of energy-based technology with Vivace Ultra™, with expected FDA Clearance, is expected to roll-out via limited commercial release in the fall to top tier plastic surgeons, dermatologists, and medical aesthetic practitioners across the country.

Key Points: 
  • "I'm honored to be joining an organization about to reignite aesthetics with Vivace Ultra and SoME PRP Skincare," says Derek Harmon.
  • "I'm impressed with what the team has created that uniquely positions ABM as a leader in this industry", he continued.
  • Mr. Harmon brings an award-winning, 20+ year career of industry expertise, results, and leadership to the ABM Executive Team.
  • ABOUT AESTHETICS BIOMEDICAL: Aesthetics Biomedical Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market.

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Retrieved on: 
Wednesday, June 29, 2022

TORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has successfully completed its research study evaluating the Company’s patented hydrogel-forming microneedle patch, PHARMAPATCH™, to deliver ketamine and KETABET™ (ketamine and betaine anhydrous), which aims to prevent the potential side effects of repeated ketamine treatment for depression and other indications, including suicidal ideation, substance abuse, post-traumatic stress disorder, neurological disorders, and chronic pain.

Key Points: 
  • Research results were published in a paper titled Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery1.
  • At regular time intervals during the 48-hour rat study, blood sample results demonstrated that PHARMAPATCH was able to deliver plasma levels of ketamine (between 70-200 ng/mL) in a controlled manner throughout the study.
  • The Company is preparing for a planned Phase 2 clinical study to allow for ketamine and KETABET microneedle patch evaluation in treatment-resistant depression and chronic pain under the FDA 505(b)(2) regulatory pathway.
  • The Companys patented hydrogel-forming microneedle (MN) patch aims to deliver ketamine for intradermal administration to treat various mental health, neurological and pain disorders.

Global Medical Microneedle Diagnostics Devices, Targets, Technology & Markets Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 26, 2022

The "Medical Microneedle Diagnostics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Microneedle Diagnostics" report has been added to ResearchAndMarkets.com's offering.
  • Medical Microneedle Diagnostics: Devices, Targets, Technology & Markets is a comprehensive evaluation and analysis of the technology, markets and competitive landscape providing the driving force behind this evolving segment of the healthcare sector.
  • Microneedle technology is attaining commercial viability at a time when healthcare providers are faced with new challenges as they assess ways to incorporate companion diagnostics into their practice areas.
  • What companies are active in the microneedle diagnostics segments, what distinguishes their technology, and what is their market presence?

PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch

Retrieved on: 
Monday, December 20, 2021

TORONTO and ANDERNACH, Germany, Dec. 20, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine products, and LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company, today announced they have entered into a process development agreement for the clinical trial scale up of PharmaThers proprietary Ketamine microneedle patch product.

Key Points: 
  • TORONTO and ANDERNACH, Germany, Dec. 20, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine products, and LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company, today announced they have entered into a process development agreement for the clinical trial scale up of PharmaThers proprietary Ketamine microneedle patch product.
  • Under the agreement, PharmaTher will cooperate with LTS in the process development and scale up of PharmaThers Ketamine microneedle patch product.
  • PharmaTher will be responsible for the planning and execution of clinical studies with the Ketamine microneedle patch product.
  • We are excited to work with LTS, a leader in transdermal delivery systems, to complete the clinical development of our ketamine microneedle patch product for clinical studies and scale up for future commercial use, said Fabio Chianelli, CEO of PharmaTher.

Healthcare Markets for Medical Microneedles to 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 28, 2021

The "Healthcare Markets for Medical Microneedles to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Healthcare Markets for Medical Microneedles to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The processing techniques incorporate one or more technologies that enable the precise machining, extrusion, casting, and/or forming of from one to an array or grid of microneedles.
  • How has technology evolved to advance the addressable market for medical microneedles?
  • What are the emerging therapeutic and diagnostic applications that are expected to drive growth in medical microneedle markets?

Micron Biomedical Initiates First-Ever Microneedle Vaccine Clinical Trial in Children

Retrieved on: 
Tuesday, July 13, 2021

Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron's Microneedle-Based Measles-Rubella Vaccine

Key Points: 
  • Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron's Microneedle-Based Measles-Rubella Vaccine
    ATLANTA, July 13, 2021 /PRNewswire/ - Micron Biomedical, Inc. ("Micron" or the "Company"), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella ("MR") vaccine.
  • The trial will assess the safety, tolerability and immunogenicity of an MR vaccine delivered using Micron's technology, compared with delivery via standard subcutaneous injection, in adults and children.
  • "This trial reinforces Micron's position as a leader in microneedle-based vaccine and drug delivery technology, and we are excited to be collaborating with Dr. Clarke and the MRCG at LSHTM on this groundbreaking clinical trial."
  • Micron is an Atlanta based company whose microneedle technology was initially developed at Georgia Tech in the lab of Mark Prausnitz, PhD.

PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals

Retrieved on: 
Tuesday, June 1, 2021

PharmaTher and TSRL share the commitment to commercialize a patented hydrogel-forming microneedle patch delivery technology licensed from Queens University of Belfast.

Key Points: 
  • PharmaTher and TSRL share the commitment to commercialize a patented hydrogel-forming microneedle patch delivery technology licensed from Queens University of Belfast.
  • Zanamivir, other antiviral therapeutics and vaccines) in a microneedle patch with the potential to improve on the safety (i.e.
  • TSRL has successfully conducted a pre-IND meeting with the US FDA and achieved agreement with the agency on their proposed 505(b)2 product development plans.
  • PharmaTher is currently conducting an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

Retrieved on: 
Tuesday, May 25, 2021

Our FDA orphan drug application for ketamine to treat this life-threatening disease complements our patent portfolio that aims to protect the proposed method of use and dosage claims of ketamine for ALS.

Key Points: 
  • Our FDA orphan drug application for ketamine to treat this life-threatening disease complements our patent portfolio that aims to protect the proposed method of use and dosage claims of ketamine for ALS.
  • The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.
  • The FDA grants orphan status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
  • PharmaTher is currently conducting an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.

Terasaki Institute for Biomedical Innovation and HTL Biotechnology Announce Memorandum of Understanding for Research in Translational Biomaterials

Retrieved on: 
Friday, May 7, 2021

b'LOS ANGELES, May 7, 2021 /PRNewswire/ --The Terasaki Institute for Biomedical Innovation (TIBI), a research institute at the frontier of personalized and precision medicine, and HTL Biotechnology, the world leader in using hyaluronic acid and other biopolymers for biotechnology solutions, announce their Memorandum of Understanding to explore the creation of a joint research program.

Key Points: 
  • b'LOS ANGELES, May 7, 2021 /PRNewswire/ --The Terasaki Institute for Biomedical Innovation (TIBI), a research institute at the frontier of personalized and precision medicine, and HTL Biotechnology, the world leader in using hyaluronic acid and other biopolymers for biotechnology solutions, announce their Memorandum of Understanding to explore the creation of a joint research program.
  • This program focuses on biomaterials for translational projects; it would combine TIBI\'s microneedle and bioprinting technologies with HTL\'s expertise in biopolymers for aesthetics, dermatology, ophthalmology, rheumatology, tissue engineering and drug delivery applications.\nThe Terasaki Institute\'s broad biomaterials research platform is expanding in size and scope.
  • "Our institute leads the world in developing bioprintable, biopolymer-based technologies poised to revolutionize drug delivery and wearable and implantable devices.
  • HTL serves the pharmaceutical and medical device industries worldwide, enabling them to transform lives of patients.

Burns & Levinson Closes $4.2 Million Seed Financing for Anodyne Nanotech

Retrieved on: 
Monday, May 3, 2021

b'BOSTON, May 3, 2021 /PRNewswire/ -- Burns & Levinson has closed a $4.2 million seed investment from Velocity Partners, Relativity Healthcare Fund and Big Pi Venturesfor Anodyne Nanotech, Inc. , a Boston-based biotechnology company developing differentiated, transdermal forms of high-value drugs.

Key Points: 
  • b'BOSTON, May 3, 2021 /PRNewswire/ -- Burns & Levinson has closed a $4.2 million seed investment from Velocity Partners, Relativity Healthcare Fund and Big Pi Venturesfor Anodyne Nanotech, Inc. , a Boston-based biotechnology company developing differentiated, transdermal forms of high-value drugs.
  • By incorporating solvent-free bulk drug substance directly into microscopic porosities, Anodyne can load unprecedented amounts of the drug onto each microneedle.
  • Anodyne Nanotech\'s primary focus is now on biologics, and we have shown delivery of monoclonal antibodies and peptides in vivo.
  • For more information, visit Burns & Levinson at www.burnslev.com .\n'